Facial and neck erythema associated with dupilumab treatment: A systematic review

Jo, Christine E.; Finstad, Alexandra; Georgakopoulos, Jorge R.; Piguet, Vincent; Yeung, Jensen; Drucker, Aaron M.

doi:10.1016/j.jaad.2021.01.012

Cited by 75 publications

(69 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Jo et al conducted a systematic review of facial and neck erythema associated with dupilumab treatment (Jo et al, 2021) We should be aware that "facial redness" is not a diagnosis but a sign. Physicians need to determine the underlying diagnosis by making the most use of their clinical acumen.…”

Section: Waldman Et Al Characterized Dupilumab Facial Redness By Retrospectively Reviewingmentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Waldman Et Al Characterized Dupilumab Facial Redness By Retrospectively Reviewingmentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Although no safety signal was detected during randomized clinical trials of dupilumab in AD, a number of individual case reports and limited case series describe a new-onset or acute worsening of facial rash associated with dupilumab treatment [18][19][20][21][22][23][24][25][26][27][28]. Reported clinical signs and symptoms include erythema, edema, flushing, papulopustules, pruritus, scaling, and a burning sensation in the centrofacial area [26,28]. Various possible etiologies have been suggested, including corticosteroid withdrawal, rosacea, contact dermatitis, Malassezia colonization involving the face and neck, seborrheic dermatitis, photosensitivity, and alcohol-induced facial flushing [19, 20, 22-25, 28, 29].…”

Section: Introductionmentioning

confidence: 99%

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks

Blauvelt

Bruin‐Weller

Simpson

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction In a 52-week, phase 3 clinical trial (LIBERTY AD CHRONOS) in adult patients with moderate-to-severe atopic dermatitis (AD), dupilumab in combination with topical corticosteroids (TCS) resulted in a significant improvement in overall Eczema Area and Severity Index (EASI) compared with placebo plus TCS. In a post hoc analysis, dupilumab significantly improved the overall extent and severity of AD across four anatomic regions (head and neck, trunk, upper extremities, lower extremities) over 16 weeks. However, as AD severity and presentation may vary by body region, this analysis sought to determine whether there are regional variations in dupilumab efficacy. Methods Using data from the LIBERTY AD CHRONOS study, we performed a post hoc analysis of the mean percentage change in individual EASI signs (erythema, infiltration/papulation, excoriation, lichenification) from baseline through week 52 across four anatomic regions (head and neck, trunk, upper extremities, lower extremities). Results Dupilumab plus TCS, compared with placebo plus TCS, significantly improved the severity of all individual AD signs to a similar extent across the four anatomic regions. Significant improvements in each sign were seen early, within the first 2–4 weeks of treatment, and were sustained through week 52 across all regions. Conclusions In adult patients with moderate-to-severe AD, treatment with dupilumab resulted in rapid and sustained improvement in the signs of AD across all anatomic regions. Trial registration LIBERTY AD CHRONOS (NCT02260986).

show abstract

“…Epidermal hyperplasia with elongation of the rete ridges was observed in some patients, resembling psoriasiform dermatitis [85]. A recent systematic review of the literature describes the clinical presentation, treatment approaches, and outcomes in patients taking dupilumab for AD [109].…”

Section: Management Of Conjunctivitis In Admentioning

confidence: 99%

Practical Management of Patients with Atopic Dermatitis on Dupilumab

Papp

Hong

Lansang

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particular interest in transitioning from current therapies and managing medication overlap, considerations for special populations of patients with AD, and management of potential adverse events. Methods This article aims to review the literature addressing several practical management issues related to dupilumab use for AD and to provide a framework for clinical decision-making in these circumstances and sub-populations. Each statement was reviewed, revised and voted on by authors to provide their level of agreement and degree of uncertainty for each statement. Results An agreement level > 80% was achieved for all of the statements. Conclusion The expert panel provides statements considering the practical management of patients with AD taking dupilumab to inform clinical decision-making in specific but frequently encountered clinical situations. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-021-00586-w.

show abstract

Facial and neck erythema associated with dupilumab treatment: A systematic review

Cited by 75 publications

References 41 publications

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks

Practical Management of Patients with Atopic Dermatitis on Dupilumab

Contact Info

Product

Resources

About